-
1.发明申请Method of treatment of diabetes and/or obesity with reduced nausea side effect 失效减少恶心副作用的糖尿病和/或肥胖症的治疗方法公开(公告)号：US20070207958A1
公开(公告)日：2007-09-06
申请号：US11595576
申请日：2006-11-09
IPC分类号： A61K38/22
CPC分类号： A61K38/26 , A61K47/643
摘要： The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.
摘要翻译： 本发明提供以有效治疗病症或病症的量施用促胰岛素肽的方法，同时通过向有需要的受试者施用与白蛋白缀合的促胰岛素肽来减轻恶心副作用。 本发明还提供了选择用于给予共轭促胰岛素肽的受试者的方法。 用促胰岛素肽治疗的示例性疾病或病症包括肥胖症和II型糖尿病。
-
公开(公告)号：US20060241019A1
公开(公告)日：2006-10-26
申请号：US10565900
申请日：2004-07-26
CPC分类号： A61K38/28 , A61K47/643 , C07K14/62
摘要： The present invention relates to an insulin derivative comprising an insulin molecule and a reactive group for covalently bonding a blood component, wherein preferably the insulin molecule is human natural insulin molecule and the reactive group is coupled to an amino acid of the insulin molecule at a position selected from the positions Gly A1, Phe B1 and Lys B29.
摘要翻译： 本发明涉及包含胰岛素分子和用于共价键合血液成分的反应性基团的胰岛素衍生物，其中优选地，胰岛素分子是人天然胰岛素分子，并且反应性基团与胰岛素分子的氨基酸在位置 选自Gly A1，Phe B1和Lys B29。
-
3.发明授权Method of treatment of diabetes and/or obesity with reduced nausea side effect 失效减少恶心副作用的糖尿病和/或肥胖症的治疗方法公开(公告)号：US08039432B2
公开(公告)日：2011-10-18
申请号：US11595576
申请日：2006-11-09
CPC分类号： A61K38/26 , A61K47/643
摘要： The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.
摘要翻译： 本发明提供以有效治疗病症或病症的量施用促胰岛素肽的方法，同时通过向有需要的受试者施用与白蛋白缀合的促胰岛素肽来减轻恶心副作用。 本发明还提供了选择用于给予共轭促胰岛素肽的受试者的方法。 用促胰岛素肽治疗的示例性疾病或病症包括肥胖症和II型糖尿病。
-
4.发明申请SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF 审中-公开用于治疗结合物的短和含氨基酸的多肽及其用途公开(公告)号：US20130280281A1
公开(公告)日：2013-10-24
申请号：US13807640
申请日：2011-07-04
摘要： The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.
摘要翻译： 本发明涉及具有一个或多个D-氨基酸作为靶向部分的短多肽（例如，长度上少于19个氨基酸）和更长的多肽（例如，长度为19个或更多个的氨基酸）。 当与试剂（例如治疗剂或转运载体）缀合时，这些多肽能够将该药物转运穿过BBB或特定的细胞类型。 特别地，短多肽可以包括一个或多个D-氨基酸。 因此，这些化合物特别可用于治疗与特定细胞类型，器官或组织相关的神经疾病或疾病。
-
公开(公告)号：US20120277158A1
公开(公告)日：2012-11-01
申请号：US13500852
申请日：2010-10-05
IPC分类号： A61K38/10 , C07K9/00 , C07K14/00 , C07K14/475 , C07K14/575 , A61K38/16 , A61P25/28 , A61P25/18 , A61P25/00 , A61P25/08 , A61P25/16 , A61P43/00 , A61P3/00 , A61P35/00 , A61P35/04 , C07K1/113 , C07K7/08 , B82Y5/00
CPC分类号： A61K47/62 , A61K47/64 , A61K47/6907 , A61K47/6911 , A61K47/6921 , A61K47/6929 , C07K7/083 , C07K14/475 , C07K14/5759 , C07K14/8117
摘要： The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.
摘要翻译： 本发明涉及包含能够穿过血脑屏障或进入连接到转运载体的一种或多种细胞类型的多肽的缀合物，即能够转运药剂（例如治疗剂）的组合物。 在某些情况下，多肽直接与脂质或聚合载体缀合，以允许靶向施用治疗剂以治疗例如癌症，神经变性疾病或溶酶体贮积病症。
-
公开(公告)号：US09161988B2
公开(公告)日：2015-10-20
申请号：US13382069
申请日：2010-06-30
申请人： Jean-Paul Castaigne , Michel Demeule , Christian Che , Carine Thiot , Catherine Gagnon , Betty Lawrence
发明人： Jean-Paul Castaigne , Michel Demeule , Christian Che , Carine Thiot , Catherine Gagnon , Betty Lawrence
CPC分类号： A61K47/48246 , A61K47/64
摘要： The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.
摘要翻译： 本发明涉及能够穿过血脑屏障（BBB）或有效进入特定细胞类型的多聚体（例如二聚体，三聚体）形式的肽载体。 当与试剂（例如治疗剂）缀合时，这些多聚体肽载体能够将该药物转运穿过BBB或特定的细胞类型。 因此，这些化合物特别可用于治疗神经疾病。
-
7.发明申请FUSION PROTEINS FOR DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM 审中-公开用于将GDNF和BDNF递送至中央神经系统的融合蛋白公开(公告)号：US20120196803A1
公开(公告)日：2012-08-02
申请号：US13377480
申请日：2010-06-11
IPC分类号： A61K38/18 , C12N15/62 , C12N15/63 , A61P25/28 , A61P25/00 , A61P25/24 , A61P25/18 , C07K19/00 , C12P21/02
CPC分类号： C07K14/4756 , A61K38/00 , A61K47/64 , C07K14/48 , C07K2319/03
摘要： The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), or a related molecule, such as an analog or a fragment thereof. The compounds of the invention may be used to treat any disease where increased neuronal survival or growth is desired, e.g., neurodegenerative diseases, such as Parkinson's disease or amyotrophic lateral sclerosis. Other diseases can be treated using the compounds include schizophrenia and depression.
摘要翻译： 本发明涉及一种化合物，其包含肽载体，例如作用于血脑屏障的载体的血管紧张素-2，与神经胶质来源的神经营养因子（GDNF），脑源性神经营养因子（BDNF）， 或相关分子，例如其类似物或片段。 本发明的化合物可用于治疗需要增加神经元存活或生长的任何疾病，例如神经变性疾病，例如帕金森病或肌萎缩性侧索硬化症。 可以使用包括精神分裂症和抑郁症在内的化合物治疗其他疾病。
-
公开(公告)号：US20120015876A1
公开(公告)日：2012-01-19
申请号：US13124013
申请日：2009-10-15
IPC分类号： A61K38/22 , A61P3/04 , A61P3/10 , C07K19/00 , C07K14/575 , C07K1/04 , A61P3/06 , A61P9/12 , A61P9/00 , A61P3/08 , A61P25/16 , A61P25/22 , A61P25/28 , A61P25/20 , A61P25/14 , A61P25/18 , A61P25/08 , A61P25/00 , A61P1/16 , A61P1/00 , A61P9/10 , A61P13/00 , A61P13/12 , A61P9/04 , A61P11/00 , A61P15/00 , A61P29/00 , C07H21/00
CPC分类号： C07K14/57563 , A61K38/00 , A61K47/64 , A61K47/65 , C07K2319/01
摘要： The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.
摘要翻译： 本发明的特征在于具有式AXB的化合物，其中A是能够增强化合物穿过血脑屏障或特定细胞类型的转运的肽载体，X是接头，B是GLP-1激动剂（例如， ，毒蜥外泌肽-4或毒蜥外泌肽-4类似物）。 本发明的化合物可用于治疗需要增加GLP-1活性的任何疾病，例如代谢疾病，例如肥胖症和糖尿病。
-
公开(公告)号：US08921314B2
公开(公告)日：2014-12-30
申请号：US13124013
申请日：2009-10-15
IPC分类号： A61K38/00 , A61P3/10 , A61P3/04 , C07K14/605 , C07K14/575 , A61K47/48
CPC分类号： C07K14/57563 , A61K38/00 , A61K47/64 , A61K47/65 , C07K2319/01
摘要： The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of the invention can be used to treat any disease where increased GLP-1 activity is desired, for example, metabolic diseases, such as obesity and diabetes.
摘要翻译： 本发明的特征在于具有式AXB的化合物，其中A是能够增强化合物穿过血脑屏障或特定细胞类型的转运的肽载体，X是接头，B是GLP-1激动剂（例如， ，毒蜥外泌肽-4或毒蜥外泌肽-4类似物）。 本发明的化合物可用于治疗需要增加GLP-1活性的任何疾病，例如代谢疾病，例如肥胖症和糖尿病。
-
公开(公告)号：US20110288009A1
公开(公告)日：2011-11-24
申请号：US13132838
申请日：2009-12-07
IPC分类号： A61K38/22 , C07K19/00 , C07H21/00 , A61P3/04 , A61P9/12 , A61P3/06 , A61P3/00 , A61P3/08 , A61P9/00 , C07K14/575 , A61P3/10
CPC分类号： C07K14/5759 , A61K38/00 , A61K47/64 , C07K14/8117 , C07K2319/10
摘要： The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a leptin, a leptin analog, or OB receptor agonist. The compounds of the invention can be used to treat any disease in which increased amounts of leptin are desired, such as metabolic diseases including obesity and diabetes.
摘要翻译： 本发明的特征在于具有式AXB的化合物，其中A是能够增强化合物穿过血脑屏障或特定细胞类型的转运的肽载体，X是接头，B是瘦蛋白，瘦蛋白类似物， 或OB受体激动剂。 本发明的化合物可用于治疗任何需要增加瘦素量的疾病，例如包括肥胖症和糖尿病在内的代谢疾病。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.024 秒)
